In a meta-analysis of randomized controlled trials, Qiao et al. summarized that the treatment of everolimus plus endocrine therapy in hormone receptor-positive and Her2/Neu receptor-negative patients caused adverse effects in patients with an approximate occurrence of 50% stomatitis, 40% rash, 33% nausea, 14% pneumonitis, 34% diarrhea, and 40% fatigue [34]; greater effects were also observed in addition to the increased injury. The gene discussed is NR4A1; the disease is stomatitis.